

# **clinical Research Input - Output**

**EU versus USA (per capita)**

**Two to three fold higher public \$\$  
investments in biomedical research in  
US  
generates two fold higher output in  
comparison with EU**

# Biomedical and clinical research

1. Public investments in biomedical and clinical research are low in comparison with health care expenditure
2. USA is outperforming EU in global biomedical and clinical research investments and output
3. This has implications
  1. for scientists and clinicians-scientists
  2. for progress in knowledge
  3. For optimal health care
  4. For optimal spending of health care \$/€
  5. For private investments in health (pharma/biotech companies/medical devices)

# Biomedical and clinical research output

## Questions

do we want to improve biomedical and clinical research in the EU ?

If so: what is best strategy?

How to bring this on the policy agenda?  
at the national or EU level?



**Ernst H. Starling to the British Research Council in 1924:**

**“Find the best of men, give them what equipment you can afford, and leave them alone”**

(Discovery of the hormone together with Bayliss, the capillary diffusion & Starling’s heart law)

# Solutions:

**Adequate Research Funding &**

**Use of “Best Practice” in R&D**

# Recommandations for strengthening medical research in Europe (EMRC 2012)

1. Best practice for funding and performing research
2. Collaboration (well funded groups are willing to cooperate if it is in their mutual interest and spare scientists from complex international grant applications whenever possible)
3. Revision of EC Directives (Clinical trials and patent laws: now (2015) done!!)
4. Equal opportunities for performing research
5. Doubling of public funding to 0.25 % of GDP

# Biomedical and clinical research 10 yrs Agenda

## Suggestions R Bouillon 2015

1. Long term strategic planning for Biomedical Research in Europe
  1. Regions – countries – EU: respect for subsidiarity
  2. Public – private investments – medical insurance companies – patient organisations
  3. basic – translational – clinical – applied/implementation research

.../...

# Biomedical and clinical research

## 10 yrs Agenda: Suggestions R Bouillon 2015

1. Long term strategic planning for Biomedical Research in Europe

2. €€€ or £££ or \$\$\$

1. For basic research: regions – countries - >> EU

2. For translational – clinical research: regions – countries & EU & insurance companies

including a solution for funding international ACADEMIC clinical research projects including support by medical insurance companies at 0.1 – 1% of health care costs:

Essential role for EU-wide ERC-like NIH-like Translational/Clinical Research Funding Institution

Example of ECRIN funding system proves that such joint EU-national funding is contra productive

3. NO STOP – GO funding



# Biomedical and clinical research

## 10 yrs Agenda: Suggestions R Bouillon 2015

1. Long term strategic planning for Biomedical Research in Europe

2. €€€ or £££ or \$\$\$

.../...

4. High quality international peer review for all funding

5. Long term career planning for all biomedical scientists with special attention for

- interdisciplinary research teams

- clinical scientists or MD-PhD as endangered species

# Biomedical Research - Recommendations



1. Citizens and patients should be closely engaged with biomedical research
2. The results of biomedical research should be rapidly and efficiently brought to the patient
3. Biomedical research should be conducted with high quality in an open, honest and transparent way
4. European biomedical research should be conducted within a global context
5. Investment should be increased to create the right world-class biomedical research

EMRC statement published in *Science Business* in November 2012:

“EMRC statement on medical research in the EU: why we need a new strategy for health research in Europe. Quousque tandem...”



# Health Research Funding in Europe

- EMRC statement published in *Science Business* in November 2012: “EMRC statement on medical research in the EU: why we need a new strategy for health research in Europe. Quousque tandem...”

Signatories: EMRC Standing Committee members and Alliance for Biomedical Research in Europe ([www.biomedeuropa.org](http://www.biomedeuropa.org))

- EMRC statement updated in March 2013 by the SRG-MED, co-signed by Science Europe Medical Scientific Committee (SE MED) chaired by Professor Richard Frackowiak (Lausanne, CH)

Signatories: SRG-MED and SE MED members

**ACTION:** create a MASTER ACTION PLAN to cover the next 10 years.